New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...